Skip to main content
. 2021 Apr 17;190:105075. doi: 10.1016/j.antiviral.2021.105075

Fig. 2.

Fig. 2

CHLA and PUG inhibit SARS-CoV-2 replication. A. Plaque reduction assay of CHLA and PUG as well as remdesivir (3 μM) against authentic SARS-CoV-2 at indicated concentrations. B. Dose-dependent inhibition of CHLA and PUG on SARS-CoV-2 replication. Antiviral activity and cytotoxicity are shown in red and blue, respectively. The EC50 and CC50 are displayed in the upper left corner for each compound. The data represent mean ± standard deviation (SD) of the triplicate measurements. IC50 values were determined by fitting the dose-response curves with four-parameter logistic regression in Prism GraphPad (version 8.1.2). All data was normalized to virus alone.